Depends on whom you ask over there lol. Dr. Reddy'
Post# of 72440
"Dr. Reddy's is a willing buyer and in a position to develop XP23829. The company is planning to integrate the drug, an oral tablet, into its existing internal development efforts, which have been focused heavily on mild-to-moderate psoriasis. Although XenoPort recently announced mixed phase 2 results, Dr. Reddy's sees real potential not only for psoriasis, but also for relapsing-remitting multiple sclerosis (RRMS)."
http://www.biopharmadive.com/news/xenoport-se...ys/416542/
Quote:
A failed drug gets $490 million? Hey, wasn't Prurisol a failure?